Trial Condition(s):

Wet age-related macular degeneration

Investigating the effectiveness of Eylea in patients with wet age-related macular degeneration (PERSEUS)

Bayer Identifier:

16623

ClinicalTrials.gov Identifier:

NCT01914380

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The study aims to investigate the effectiveness of Eylea in patients with wet age-related macular degeneration in routine clinical practice in Germany. The study is purely observational, only data from routine treatment are to be collected. The treatment and treatment conditions are solely at discretion of the treating physician.

Inclusion Criteria
-  Patients with wet wAMD treated with Eylea (in accordance with the local Summary of Product Characteristics, SPC).
 -  Written informed consent.
Exclusion Criteria
-  Exclusion criteria as listed in the local SPC.
 -  Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
 -  Any concomitant therapy with another agent to treat wet AMD in the study eye.

Trial Summary

Enrollment Goal
988
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 

Trial Design